Douglas Yee

发表

Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development.

David Wholley, Anne Wallace, Michael Hogarth, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2.

Donald A. Berry, Nola M. Hylton, Rita Nanda, 2017 .

Crosstalk Between IGF1R and Estrogen Receptor Signaling in Breast Cancer

D. Yee, Douglas Yee, Dedra H. Fagan, 2008, Journal of Mammary Gland Biology and Neoplasia.

Potential therapeutic strategies to interrupt insulin-like growth factor signaling in breast cancer.

Sara A Byron, S. Byron, D. Yee, 2003, Seminars in oncology.

Detection and downregulation of type I IGF receptor expression by antibody-conjugated quantum dots in breast cancer cells

Allison Hubel, D. Yee, Chun Wang, 2009, Breast Cancer Research and Treatment.

Quantum dots for cancer diagnosis and therapy: biological and clinical perspectives.

D. Yee, Chun Wang, Hua Zhang, 2008, Nanomedicine.

New Mechanisms of Signal Transduction Inhibitor Action

Steffi Oesterreich, Adrian V. Lee, Rachel Schiff, 2003 .

Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study.

D. Yee, Jeffrey S. Miller, E. Chiorean, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Imaging in breast cancer: Magnetic resonance spectroscopy

Michael Garwood, Patrick J Bolan, M. Garwood, 2005, Breast Cancer Research.

In vivo quantification of choline compounds in the breast with 1H MR spectroscopy

Michael Garwood, Patrick J Bolan, D. Yee, 2003, Magnetic resonance in medicine.

Insulin‐like growth factor (IGF)‐I rescues breast cancer cells from chemotherapy‐induced cell death – proliferative and anti‐apoptotic effects

D. Yee, Douglas Yee, Jennifer L. Gooch, 1999, Breast Cancer Research and Treatment.

The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer

Reuben S Harris, Rachel Isaksson Vogel, John W M Martens, 2016, Science Advances.

Pharmacodynamic Modeling of Sequence-Dependent Antitumor Activity of Insulin-like Growth Factor Blockade and Gemcitabine

Richard C. Brundage, Amit Khatri, D. Yee, 2011, The AAPS Journal.

Eliminating spurious lipid sidebands in 1H MRS of breast lesions

Hellmut Merkle, Michael Garwood, Lance DelaBarre, 2002, Magnetic resonance in medicine.

MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial

Elizabeth A Morris, Constantine A Gatsonis, Michael Garwood, 2017, Journal of magnetic resonance imaging : JMRI.

Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.

Anne M Wallace, Michael Hogarth, Lajos Pusztai, 2016, The New England journal of medicine.

STAT6 mediates interleukin-4 growth inhibition in human breast cancer cells.

D. Yee, B. Christy, Douglas Yee, 2002, Neoplasia.

New mechanisms of signal transduction inhibitor action: receptor tyrosine kinase down-regulation and blockade of signal transactivation.

Steffi Oesterreich, Adrian V. Lee, Adrian V Lee, 2003, Clinical Cancer Research.

Diabetes and Cancer

Edward Giovannucci, D. Harlan, D. Yee, 2010, Diabetes Care.

Exogenous near-infrared fluorophores and their applications in cancer diagnosis: biological and clinical perspectives.

D. Yee, Hua Zhang, Douglas Yee, 2011, Expert opinion on medical diagnostics.

Adaptive Randomization of Neratinib in Early Breast Cancer.

Michael Hogarth, Lajos Pusztai, Rita Nanda, 2016, The New England journal of medicine.

Revisiting the IGF-1R as a breast cancer target

D. Yee, Douglas Yee, Roudy Chiminch Ekyalongo, 2017, npj Precision Oncology.

Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer.

D. Yee, C. Lange, Douglas Yee, 2011, Endocrine-related cancer.

Metabolite quantification and high‐field MRS in breast cancer

Michael Garwood, D. Yee, M. Nelson, 2009, NMR in biomedicine.

The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer

Anne Wallace, Emanuel F Petricoin, Rita Nanda, 2015, Clinical Cancer Research.